会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
    • 非水性注射制剂,pH调节用于生长激素的延长释放
    • US06664234B1
    • 2003-12-16
    • US09894058
    • 2001-06-28
    • Daniel N. HeintzYunhua N. Jeng
    • Daniel N. HeintzYunhua N. Jeng
    • A61K3818
    • A61K38/27
    • The present invention provides compositions of matter which allow for the extended release and enhanced bioavailability of biologically-active polypeptides following parenteral delivery to an animal. More particularly, it concerns compositions comprising biologically-active somatotropin formulated for extended release, methods of preparing these compositions, and methods of using the same. These compositions comprise somatotropin, a pH-adjusting constituent (PAC), and a substantially non-aqueous, hydrophobic excipient. The PAC may comprise any suitable, biocompatible compound including, but not limited to one or mixtures of two or more of the following: acetic acid, phosphoric acid, monobasic phosphate. The PAC is added to the compositions of matter in an amount effective to adjust the pH to or near to the isoelectric point (pI) of the somatotropin component.
    • 本发明提供了一种物质组合物,其允许在肠胃外递送至动物后延长释放并增加生物活性多肽的生物利用度。 更具体地,涉及包含用于延长释放的生物活性生长激素配制剂,制备这些组合物的方法和使用该组合物的方法的组合物。 这些组合物包含生长激素,pH调节成分(PAC)和基本上非水性疏水赋形剂。 PAC可以包括任何合适的生物相容性化合物,包括但不限于以下两种或多种的一种或多种混合物:乙酸,磷酸,一元磷酸盐。 将PAC加入到物质组合物中,其量有效地将pH调节至或接近生长激素组分的等电点(pI)。
    • 9. 发明授权
    • SMDF and GGF neuregulin splice variant isoforms and uses thereof
    • SMDF和GGF神经调节蛋白剪接变体同种型及其用途
    • US06602851B1
    • 2003-08-05
    • US09684708
    • 2000-10-06
    • Steven L. Carroll
    • Steven L. Carroll
    • A61K3818
    • C07K14/4756Y10S514/903
    • Distinct cDNAs encoding six cysteine-rich domain-NRGs and four glial growth factor isoforms were identified and sequenced. Additional heterogeneity is found in the EGF-like (&agr;- and &bgr;-isoforms) and carboxy terminal (a and b variant) regions of CRD-NRGs. Furthermore, the predicted GGF proteins contain glycosylation domains previously found only in mesenchymal NRGs. GGF mRNAs accumulate in axotomized nerve, a subpopulation of DRG neurons and most spinal cord motoneurons. CRD-NRGs, however, are undetectable in injured nerve except by RT-PCR. In contrast, the majority of DRG and spinal cord motor neurons express CRD-NRGs, with a &bgr;1 isoform being most abundant and at least some of these proteins are secreted in a form capable of activating erbB receptors. Thus, GGF and CRD-NRG subfamilies are more structurally diverse than previously appreciated. NRG actions during Wallerian degeneration may be modulated by the action of distinct splice variants.
    • 鉴定并测序编码六个富含半胱氨酸的结构域NRG和四个胶质细胞生长因子同种型的不同的cDNA。 在CRD-NRGs的EGF样(α-和β-同种型)和羧基末端(a和b变体)区域中发现另外的异质性。 此外,预测的GGF蛋白含有之前仅在间充质NRG中发现的糖基化结构域。 GGF mRNA积聚在轴突神经中,DRG神经元和大多数脊髓运动神经元的亚群。 然而,CRD-NRGs在受损的神经中是不可检测的,除了通过RT-PCR。 相比之下,大多数DRG和脊髓运动神经元表达CRD-NRG,其中β1同种型最丰富,并且这些蛋白质中的至少一些以能够激活erbB受体的形式分泌。 因此,GGF和CRD-NRG亚家族在结构上比以前更为多样化。 Wallerian退化期间的NRG作用可能受到不同剪接变体的作用的调节。